Publications by authors named "David Fudman"

Article Synopsis
  • * These guidelines are designed to support physicians in making informed decisions about CRC screening for patients who do not have specific genetic syndromes.
  • * Recent updates include insights on both primary and secondary CRC prevention, particularly addressing when to start screening for average-risk individuals and those with a relevant personal history of cancer.
View Article and Find Full Text PDF
Article Synopsis
  • The last 5 years have seen significant advancements in the treatment options for inflammatory bowel diseases, introducing new oral small molecule drugs and biologics.
  • New treatments include Janus kinase inhibitors like upadacitinib and tofacitinib, sphingosine 1-phosphate receptor modulators such as ozanimod and etrasimod, and interleukin-23 antagonists like risankizumab and mirikizumab.
  • The review emphasizes the practical application of these therapies, considering factors like effectiveness, safety data, dosing, and special situations, while suggesting a personalized approach based on each patient’s unique condition and preferences.
View Article and Find Full Text PDF

Background & Aims: Safety of biologic agents is a key consideration in patients with inflammatory bowel disease (IBD) and active or recent cancer. We compared the safety of tumor necrosis factor (TNF)-α antagonists vs non-TNF biologics in patients with IBD with active or recent cancer.

Methods: We conducted a multicenter retrospective cohort study of patients with IBD and either active cancer (cohort A) or recent prior cancer (within ≤5 years; cohort B) who were treated with TNFα antagonists or non-TNF biologics after their cancer diagnosis.

View Article and Find Full Text PDF

Low socioeconomic status (SES) is associated with greater morbidity and increased healthcare resource utilization (HRU) in IBD. We examined whether a financial assistance program (FAP) to improve healthcare access affected outcomes and HRU in a cohort of indigent IBD patients requiring biologics. IBD patients (>18 years) receiving care at a ‘safety-net’ hospital who initiated biologics as outpatients between 1 January 2010 and 1 January 2019 were included.

View Article and Find Full Text PDF

Background: Combining biologics and small molecules could potentially overcome the plateau of drug efficacy in inflammatory bowel disease (IBD). We conducted a systematic review and meta-analysis to assess the safety and effectiveness of dual biologic therapy (DBT), or small molecule combined with a biologic therapy (SBT) in IBD patients.

Methods: We searched MEDLINE, EMBASE, Scopus, Web of Science, Cochrane Database of Systematic Reviews, and Clinical trials.

View Article and Find Full Text PDF

Background And Aims: The use of forceps for removal of nondiminutive polyps is associated with incomplete resection compared with snare polypectomy. However, few studies have characterized the frequency of forceps polypectomy for nondiminutive polyps or identified strategies to improve this practice. To address this gap, we estimated the prevalence and predictors of forceps polypectomy in clinical practice and examined the effectiveness of a multicomponent intervention to reduce inappropriate forceps polypectomy.

View Article and Find Full Text PDF

Background & Aims: Inflammatory bowel disease (IBD) care and outcomes exhibit substantial variability, suggesting quality gaps. We aimed to identify interventions to narrow these gaps.

Methods: We performed a systematic review of Medline, Embase, and Web of Science through May 2021 to find manuscripts and abstracts reporting quality improvement (QI) interventions in IBD.

View Article and Find Full Text PDF

Background: Data describing the effect of obesity on antitumor necrosis factor (anti-TNF) treatment response are inconsistent. Visceral adipose tissue (VAT) is a superior marker of adiposity to body mass index. However, its effect on treatment response is unclear.

View Article and Find Full Text PDF
Article Synopsis
  • A study examined the outcomes of 14 patients with inflammatory bowel disease (IBD) who received a combination of vedolizumab with other therapies like tofacitinib, ustekinumab, or adalimumab from 2016 to 2020.
  • Results showed that 56% of patients achieved normal inflammatory markers, with significant reductions in C-reactive protein and calprotectin levels, indicating improved disease activity.
  • The combination therapy was generally well tolerated, leading to reduced steroid use in many patients, although some discontinued due to nonresponse or other reasons.
View Article and Find Full Text PDF

Background: Hyperbaric oxygen has been reported to improve disease activity in hospitalised ulcerative colitis (UC) patients.

Aim: To evaluate dosing strategies with hyperbaric oxygen for hospitalised UC patients.

Methods: We enrolled UC patients hospitalised for acute flares (Mayo score 6-12).

View Article and Find Full Text PDF

Acute severe ulcerative colitis (ASUC) is a potentially life-threatening presentation of ulcerative colitis that in nearly all cases requires inpatient management and coordinated care from hospitalists, gastroenterologists, and surgeons. Even with ideal care, a substantial proportion of patients will ultimately require colectomy, but most patients can avoid surgery with intravenous corticosteroid treatment and if needed, appropriate rescue therapy with infliximab or cyclosporine. In-hospital management requires not only therapies to reduce the inflammation at the heart of the disease process, but also to avoid complications of the disease and its treatment.

View Article and Find Full Text PDF

Background: Although esophagogastroduodenoscopy (EGD) is usually the first procedure trainees learn, it is not known whether the involvement of a trainee affects the procedure's complication rate, a key quality and safety indicator. The purpose of this study was to determine whether the complication rate of fellow-performed upper endoscopy differs from that of attending gastroenterologists, and whether that difference varies with the level of training.

Methods: Emergency room visits within 14 days of an outpatient EGD deemed to be probably or definitely related to the EGD were categorized as complications.

View Article and Find Full Text PDF

Background And Aims: Informed consent is a vital preprocedural step for endoscopy but there are substantial variations in its delivery. We therefore sought to assess a multifaceted intervention to improve the consent process.

Methods: Gastroenterologists at a tertiary center were educated on the recommended components of informed consent.

View Article and Find Full Text PDF

Radiofrequency ablation (RFA), with or without endoscopic mucosal resection (EMR), is a safe, effective, and durable treatment option for Barrett esophagus (BE)-associated dysplasia (DYS), but few studies have identified predictors of treatment failure in BE-associated intramucosal adenocarcinoma (IMC). The aim of this study was to determine the rate of IMC eradication when using RFA±EMR and to identify clinical and pathologic predictors of treatment failure. A retrospective review of medical records and a central review of index histologic parameters were performed for 78 patients who underwent RFA±EMR as the primary treatment for biopsy-proven IMC at 4 academic tertiary medical centers.

View Article and Find Full Text PDF

Background: Radiofrequency ablation (RFA) has become an accepted form of endoscopic treatment for Barrett's esophagus (BE), yet reported response rates are variable. There are no accepted quality measures for performing RFA, and provider-level characteristics may influence RFA outcomes.

Objective: To determine whether endoscopist RFA volume is associated with rates of complete remission of intestinal metaplasia (CRIM) after RFA in patients with BE.

View Article and Find Full Text PDF